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Abstract
Background: In The Netherlands the largest human Q fever outbreak ever reported in the literature is currently
ongoing with more than 2300 notified cases in 2009. Pregnant women are particularly at risk as Q fever during
pregnancy may cause maternal and obstetric complications. Since the majority of infected pregnant women are
asymptomatic, a screening strategy might be of great value to reduce Q fever related complications. We designed
a trial to assess the (cost-)effectiveness of a screening program for Q fever in pregnant women living in risks areas
in The Netherlands.
Methods/design: We will conduct a clustered randomized controlled trial in which primary care midwife centres
in Q fever risk areas are randomized to recruit pregnant women for either the control group or the intervention
group. In both groups a blood sample is taken around 20 weeks postmenstrual age. In the intervention group, this
sample is immediately analyzed by indirect immunofluorescence assay for detection of IgG and IgM antibodies
using a sensitive cut-off level of 1:32. In case of an active Q fever infection, antibiotic treatment is recommended
and serological follow up is performed. In the control group, serum is frozen for analysis after delivery. The primary
endpoint is a maternal (chronic Q fever or reactivation) or obstetric complication (low birth weight, preterm
delivery or fetal death) in Q fever positive women. Secondary aims pertain to the course of infection in pregnant
women, diagnostic accuracy of laboratory tests used for screening, histo-pathological abnormalities of the placenta
of Q fever positive women, side effects of therapy, and costs. The analysis will be according to the intention-to-
screen principle, and cost-effectiveness analysis will be performed by comparing the direct and indirect costs
between the intervention and control group.
Discussion: With this study we aim to provide insight into the balance of risks of undetected and detected
Q fever during pregnancy.
Trial registration: ClinicalTrials.gov, protocol record NL30340.042.09.
Background
Q fever, a zoonosis caused by Coxiella burnetii (C. bur-
netii), primarily infects ruminants and rodents [1]. Espe-
cially pregnancy products of infected animals like
placentas and amniotic fluid can contain high numbers
of bacteria. After drying, the organism spreads in
aerosols and remains virulent for months. Humans are
infected by inhalation of these contaminated aerosols.
Most of the infected patients are either asymptomatic or
present with a mild flu-like illness. However, Q fever
may pose a serious threat to certain groups at risk,
including pregnant women, immune compromised hosts
and individuals with pre-existing cardiac valve or vascu-
lar defects [1,2]. In The Netherlands, the number of
human cases of Q fever has dramatically increased from
around 12 cases each year before 2007 to more than
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several meetings of the Dutch Outbreak Management
Team (OMT) of the Ministry of Health to curb the epi-
demic. Studies revealed that the epidemic among Dutch
inhabitants was a result of Q fever outbreaks on dairy
goat farms [6].
Pregnant women are by far the largest risk group in
size. When infected by C. burnetii,m o s tp r e g n a n t
women will remain asymptomatic: percentages up to
90% have been described compared to 60% in the gen-
eral population [7,8]. Notably, serious complications due
to Q fever seem to occur more frequently during preg-
nancy if the infection is undetected and untreated. Preg-
nant women have an increased risk to develop chronic
Q fever or to reactivate a past infection [9,10]. Further-
more, obstetric complications related to C. burnetii
infection have been described. A landmark study from
France showed obstetric complications including sponta-
neous abortion, preterm delivery, intrauterine growth
restriction, oligohydramnios and fetal death in 81% of
t h e5 3w o m e nw h ow e r ep o s i t i v ef o rQf e v e ra n dn o t
sufficiently treated with antibiotics [10]. However,
because of the retrospective design selection bias might
have led to overestimation of the complication preva-
lence. In a Canadian cohort study in an affected area,
3.8% of parturient women had evidence of previous
exposure to C. burnetii. These women had higher risks
for adverse obstetrical outcome in terms of premature
delivery and prior or current neonatal death [11]. Little
is known about the chances of vertical transmission
from mother to child. Transmission across the placenta,
transmission by inhalation of infected amniotic fluid or
by ingestion of infected milk cannot be excluded.
Because most infected pregnant women remain
asymptomatic, one of the suggested measures to prevent
obstetric complications and maternal chronicity con-
cerns a screening strategy. However, because of lack of
information on the prevalence during pregnancy and
lack of randomized controlled trials weighing potential
benefits and risks associated with screening, evidence
for its potential impact is scarce. The Health Council of
The Netherlands therefore advised the Ministry of
Health in 2008 to facilitate studies to inform decision
makers. We therefore designed a trial to assess the
effects of a screening policy for Q fever in pregnant
women from areas with large numbers of Q fever cases
on the pregnancy outcome and cost-effectiveness from a
societal and health care perspective. The study will pri-
marily provide insights into the balance of risks of unde-
tected and detected Q fever during pregnancy.
Methods/Design
Since ethical issues surrounding randomization of the
individual pregnant woman for a Q fever screening or
non-screening strategy could seriously threaten approval
by an ethics committee, we designed a clustered rando-
mized controlled trial in which primary care midwife
centres are randomized to recruit either pregnant
women for the control group or for the intervention
group. In this way, the choice for either strategy by indi-
vidual eligible women was avoided. Timing and phasing
after eligibility checks are shown in figure 1. The study
will be conducted according to the principles of the
Declaration of Helsinki. The study protocol is approved
by the Medical Ethical Review Board of the University
Medical Centre Groningen. The study protocol is regis-
tered at http://ClinicalTrials.gov, protocol record
NL30340.042.09. The inclusion of participants started in
April 2010.
The conduct of the trial is currently supported by the
Royal Dutch Society for Midwifery (KNOV), the profes-
sional organization of midwives. Midwife centres in risk
areas for Q fever (incidence in 2009 of more than
50:100,000 inhabitants according to the National Insti-
tute for Public Health and the Environment (RIVM)),
were primarily invited to facilitate inclusion of partici-
pants. During spring 2010 we expanded the area based
on the incidence of 2010. All obstetricians, paediatri-
cians, medical microbiologists and pathologists in these
areas were informed about the study.
Inclusion criteria
Pregnant women, 18 years of age or older, with an esti-
mated date of delivery between June 1
st and December
31
st 2010, and under supervision of a midwife in primary
health care are eligible for inclusion. In The Netherlands,
midwives working in primary health care are allowed to
only supervise uncomplicated, singleton pregnancies. It is
estimated that approximately 10,000 eligible pregnant
women live in the Q fever affected areas.
Exclusion criteria
Women who do not have access to internet and/or an
email address are excluded because data collection is
web-based. In addition, women who are unable to
understand Dutch or to give informed consent, or who
have previously been tested positive for Q fever are
ineligible for participation into the study.
Experimental procedure
Intervention group
Participants who are recruited by a midwife centre ran-
domized for the intervention group are asked for a
blood sample around 20 weeks postmenstrual age. If
possible the visit is combined with the routine structural
ultrasound scan around that time. If the participant is
included after 20 weeks, the blood sample will be taken
as soon as possible after inclusion. The sample will
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in the laboratory of the Jeroen Bosch Hospital which
has analyzed most samples during the epidemic in 2007,
2008, and 2009. Serologic diagnosis of Q fever will be
made by indirect immunofluorescence assay (IFA), the
reference method for serodiagnosis of Q fever [12]. Both
IgM and IgG antibodies against phase I and phase II
antigens are measured according to the manufacturer’s
instructions (Focus Diagnostics, Cypress, CA, USA).
Titres ≥ 1:32 are considered positive. All positive sam-
ples will be fully titrated to reduce the chance of treat-
ment in false positives. In general, the first antibody to
appear in acute Q fever patients is IgM phase II,
followed by a more or less simultaneous IgG phase II
and IgM phase I response and subsequent appearance
of IgG phase I antibodies (see figure 2) [13]. This time-
dependent serologic profile allows us to discriminate
between a recent acute infection, a past infection, and a
chronic infection. If the pregnant woman does not have
evidence for an acute, past or chronic Q fever infection,
standard care will be provided.
In case of acute Q fever, the participant will be referred
to an obstetrician, and treatment will be advised accord-
ing to the local hospital protocol. In the literature, the
first choice treatment of Q fever during pregnancy is oral
cotrimoxazole (sulfamethoxazole/trimethoprim) for at
Figure 1 Timing and phasing of the study.
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cal care and serological follow up will be supervised by
the obstetrician in collaboration with the medical micro-
biologist. The current routine for pregnant women being
treated for acute Q fever is to perform monthly blood
analyses to detect the development of chronic Q fever. If
the titres decline, the frequency of these controls is scaled
down to once every two months during pregnancy, and
at 3, 6 and 12 months after delivery. If chronic Q fever
develops, treatment will be continued until the end of
pregnancy followed by bactericidal treatment with doxy-
cycline and hydroxychloroquine after delivery. In Q fever
cases placentas will be collected for polymerase chain
reaction (PCR) and histo-pathology.
I ft h e r ei se v i d e n c ef o rap a s ti n f e c t i o n ,n ot r e a t m e n t
is started. However, midwives will be advised to perform
an extra serological analysis later in pregnancy to
exclude reactivation.
Control group
Participants who are recruited by a midwife centre ran-
domly allocated to the control group will also be asked
for a blood sample around 20 weeks postmenstrual age.
These blood samples will be stored at -20°C, and ana-
lyzed for C. burnetii after delivery. In case of a positive
test, the participant’s general practitioner will be advised
to perform an extra serological analysis to exclude
chronic Q fever. Antibiotic treatment will be started if
needed according to the local protocol.
Neonates
All neonates born to Q fever positive mothers will
receive care according to the local hospital protocols.
The Section for Paediatric Infectious Diseases and
Immunology of the Dutch Paediatric Society has formu-
lated a consensus guideline for neonates born to Q fever
positive women during pregnancy [14]. The guideline
advices PCR at birth and one month of age, and
serological follow up until 18 months of age in case of
active maternal Q fever during pregnancy to diagnose
and treat potential mother-to-child transmission. Pre-
ventive antibiotic treatment is not advised. Breastfeeding
is contraindicated if maternal serum or milk is C. burne-
tii PCR positive. Breastfeeding might also be contraindi-
cated in case of maternal medication use.
Randomization procedure
Participating midwife centres are randomized to include
either pregnant women for the control group or for the
intervention group. Randomization is stratified accord-
ing to the risk of contracting a C. burnetii infection as
determined by the number of goat farms in the neigh-
bourhood (registration by Statistics Netherlands (CBS)),
and by the size of the midwife centre.
Inclusion of participants
Pregnant women are invited by their midwife to partici-
pate in the study. The informed consent procedure will
be performed by the researchers.
Data collection
Data will be collected in four ways using a structured
case record file:
1. Serological samples will be collected at the time
points described in the section Experimental procedure,
and will be analyzed in the laboratory of the Jeroen
Bosch Hospital.
2. Questionnaires; two questionnaires will be filled
out by the participant and one will be filled out by the
midwife/obstetrician.
At baseline, when the participant is included in the
trial, a questionnaire is completed by all participants
including questions about the current pregnancy, out-
come of previous pregnancies, smoking and alcohol
habits, co morbidities, medication use and demographic
characteristics. With this questionnaire risk factors are
assessed for complicated pregnancy outcome. After
delivery all relevant outcome data on obstetric complica-
tions are collected by a questionnaire completed by the
midwife. Questionnaires for participants who are
referred to a hospital during pregnancy or delivery, are
filled out by the obstetrician. During follow up, all
health care and potential cost data will be measured by
a third questionnaire completed by the participant one
month after delivery. With this questionnaire we will
also verify symptoms during pregnancy, health-related
quality-of-life (using EQ5D [15]), depressive symptoms
and fatigue (using the Shortened Fatigue Questionnaire
[16]), potential long-term consequences of Q fever, tol-
erance to antibiotic treatment and problems and devel-
opment of the newborn. Furthermore, the risk for
Q fever infection will be assessed.
Figure 2 Idealised antibody responses in acute Q fever as
measured by IFA
13.
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performed by the local microbiologists and pathologists.
Re-evaluation of the histological slides will be performed
b yo n ep a t h o l o g i s ta tt h eU n i v e r s i t yM e d i c a lC e n t r e
Groningen.
4. Medical data in primary care; data on the health
status of the participant or the newborn is collected
from medical files of the general practitioner.
Outcome measures
The primary endpoint is a maternal (chronic Q fever or
reactivation) or obstetric complication (low birth weight,
preterm delivery or fetal death) after the first trimester
of pregnancy in Q fever positive women.
The secondary endpoints are direct and indirect costs
of the screening program compared to costs of compli-
cations which could be prevented by screening. Further-
m o r e ,w ea i mt oa s s e s st h ec o u r s eo fi n f e c t i o ni n
p r e g n a n tw o m e n ,t h ea c c u r a c yo ft h ed i a g n o s t i ct e s t s
used for screening, histo-pathological abnormalities of
the placenta of Q fever infected women, and side effects
associated with treatment.
Withdrawal of individual participants
Participants are informed that they can withdraw from
t h es t u d ya ta n yt i m ep o i n t ,w i t h o u tg i v i n gar e a s o nf o r
withdrawal. If the blood sample has already been taken,
participants will be asked to give permission for collect-
ing data on obstetric outcome. Participants who with-
draw will receive regular health care according to the
local protocols.
Sample size calculation and statistics
Based on the literature and pilot data from The Nether-
lands, we expect that 12% of pregnant women in the
high-risk areas will have ser o l o g i c a le v i d e n c ef o raQ
fever infection [17,18]. Of these women, we conserva-
tively estimate that 25% will develop complications, so
3% of women will have the primary outcome. Assuming
a reduction of the complication rate of 50% by early
detection with screening during pregnancy, we will need
a participation of at least 3,400 participants with com-
plete follow up (statistical power of 80 percent, p ≤
0.05). Assuming a loss to follow up of 10% and to allow
for a small clustering effect, we aim to include 4,000
participants.
Data will be analyzed according to intention-to-screen
principles. A two-sided p-value of 0.05 or less will be
considered to indicate statistically significant. Descriptive
statistics concerning the distributions of the predictor
variables and outcome variables will be performed using
the software SPSS for windows (version 16). For univari-
ate analysis the chi-square test and Fischer’s exact test
will be used to compare proportions. For variables with
a normal distribution, differences will be analysed with
Student’s t-test. In case of non-parametric distribution,
differences between populations will either be evaluated
using the Mann-Whitney-U test or the data will be log-
transformed to obtain a normal distribution. Relative
r i s k sa sw e l la sa b s o l u t er i s kr e d u c t i o n sa n dn u m b e r s
needed to treat will be estimated with their correspond-
ing 95% confidence intervals. Possible clustering of out-
come data will be taken into account using generalised
estimating equations (GEE) modelling.
Economic evaluation
The study will primarily provide insights into the eco-
nomical balance of undetected and detected Q fever
during pregnancy. The economic evaluation will be per-
formed from a societal and health care perspective.
Direct medical and non-medical costs (laboratory costs,
costs of health care following positive screening, time,
and travel costs) as well as indirect costs (loss of pro-
ductivity) will be taken into account. The time horizon
will be from taking the blood sample until one month
after delivery for measured and calculated costs and
until one year after delivery for estimated costs. Data on
health care use and productivity loss will be collected by
questionnaires. Unit costs will be based on the Dutch
2004 guidelines for costing in health care research and
indexed for base year 2010 using yearly general consu-
mer price indices [19].
Discussion
Right at the beginning of the first Q fever outbreak in
The Netherlands in 2007, the government and health
care providers assessed the risk of Q fever related to the
outcome of pregnancies [20]. In all, only research from
France is currently available on the risks of Q fever dur-
ing pregnancy and the benefits of long-term antibiotic
treatment [10]. There is, however, a lack of data on the
prevalence and the risk of Q fever infection and the
impact of antibiotic treatment during pregnancy in
other countries such as The Netherlands. Therefore, in
December 2008 the Dutch Health Council advised the
Ministry of Health not to screen for Q fever during
pregnancy until additional scientific data would be avail-
able to support screening [20]. The Dutch outbreak is
an opportunity to gain more knowledge in this field.
Therefore we will conduct the study described pre-
viously, to provide insights into the balance of risks of
undetected and detected Q fever during pregnancy. By
the end of February 2011 all data will be available for
analysis. First results are expected in spring 2011.
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